Generate Biomedicines, Inc. is a clinical-stage generative biology company that integrates machine learning with large-scale experimentation to design proteins with defined biological intent. The company develops protein-based medicines across multiple disease areas, including airway diseases and metabolic disorders. Its lead candidate, GB-0895, is a TSLP-binding protein in Phase 3 trials for severe asthma and Phase 1 trials for COPD. Generate Biomedicines collaborates with Zealand Pharma on AI-engineered protein therapeutics for metabolic diseases and partners with Roswell Park on an armored CAR T therapy for ovarian cancer. Founded in 2018, the company unifies computational design and clinical development to streamline the drug generation process.

Summarised from the company's own disclosures

Industry Biotechnology Homepage investors.generatebiomedicines.com
Sector Healthcare IR page investors.generatebiomedicines.com
Tags
generative biology, protein therapeutics, machine learning, asthma, copd, metabolic diseases, ovarian cancer, car t therapy, tslp inhibitors, GB-0895, Zealand Pharma, Roswell Park
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 10
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Revenue 4.22M 6.314M 7.224M
Net profit -87.657M -67.255M -61.446M
Free cash flow -57.012M -58.877M -84.169M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 15.02 16.87 12.5
P/FCF -8.5 -9.19 -4.76

Filed figures

Figure Dec 2025
Balance sheet detail
Lease liabilities (USD) 68.5M
Cash and deposits (USD) 122M
Right-of-use assets (USD) 59.9M
Reported May 7, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD

Zealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearly $1.2 billion in total potential milestones, plus tiered royalties

Anthropic collaboration builds on AI agent–guided CAR T research yielding smaller signaling domains with improved function in preclinical studies

Oncology clinical programs advance with second-cohort enrollment for GB-4362 in advanced urothelial cancer and first-patient dosing of GB-5267 in platinum-resistant ovarian cancer

Cash, cash equivalents, and marketable securities of $404.2 million as of Sept. 30, 2026

SOMERVILLE, Mass., Nov. 12, 2026 — Generate Biomedicines, Inc. (Nasdaq: GENB) (“Generate”) today reported financial results for the third quarter ended Sept. 30, 2026, and provided an update on recent business progress.

“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence,” said Mike Nally, chief executive officer of Generate Biomedicines.

Generate Biomedicines, Inc. — Regulation FD Disclosure Bull 5 Bear 0 Clinical/regulatory

On August 25, 2026, draft copies of three posters submitted by Generate Biomedicines, Inc. (the “Company”) and accepted for presentation at the European Respiratory Society Congress 2026 (“ERS”), scheduled for September 5-9, 2026, were inadvertently made publicly available via the ERS website prior to the expiration of the applicable embargo, which the Company believed would run until 6:01 p.m., Eastern time, on September 7, 2026. The draft posters include results of ongoing clinical trials sponsored by the Company and are entitled:
•“GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients”;

•“SOLAIRIA-1 & SOLAIRIA-2: Two Phase 3 randomized, double-blind, placebo-controlled studies of GB-0895, a long-acting anti-TSLP antibody, in severe uncontrolled asthma”; and

•“GB-0895, a High-Affinity Anti-TSLP Antibody, Demonstrates Potent and Sustained Pharmacological Activity in Adults with COPD.”

As a precautionary measure, the Company is providing the final posters attached hereto as Exhibit 99.1, which include the information that was furnished to ERS.

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions

Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8

All patients enrolled in first cohort of the Phase 1 study for GB-4362 (MMAE neutralizer)

Platform advancements extend across strategic collaborations

Approximately $457.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026

SOMERVILLE, Mass., Aug. 6, 2026 — Generate Biomedicines Inc. (NASDAQ: GENB) (“Generate”) today reported financial results for the second quarter ended June 30, 2026, and highlighted continued progress across its platform, pipeline, and collaborations.

“Our team’s focus on execution for our clinical programs and translating our generative biology platform into the next generation of differentiated medicines drove strong progress in the second quarter,” said Mike Nally, chief executive officer of Generate Biomedicines Inc. “With GB-0895, our global Phase 3 SOLAIRIA studies in severe asthma continue to advance.

Prompts

Generate Biomedicines, Inc. (ticker GENB), listed in United States.

ETFs Holding Generate Biomedicines, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 0.92% 1,700,605 $ 16.734M Nov 18, 2026
JTEK 0.07% 290,218 $ 2.856M Nov 17, 2026
RESM 0.03% 64 $ 1,079.68 Jun 30, 2026
AVUS 0.00% 16,259 $ 170.557K Nov 16, 2026